EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Cost-effectiveness of incretin therapies: a Canadian lens on diabetes, obesity, and emerging indications

Luke Awadalla, Siena Iskander, Cherry Chu, Mina Tadrous iD

Canadian Journal of Physiology and Pharmacology · 2026

DOI: 10.1139/cjpp-2025-0248 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Canadian Journal of Physiology and Pharmacology, 2026. Verfasst von Luke Awadalla und 3 weiteren Autor:innen. Beteiligte Einrichtung: Western University, London, ON, Canada. Hauptthemen laut MEDLINE: Incretins, Cost-Benefit Analysis, Diabetes Mellitus, Type 2, Obesity. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 61 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Incretin therapies have emerged as key interventions for glycemic control and weight reduction and are now among Canada’s costliest outpatient drug classes. This review synthesizes current clinical and economic evidence on the cost-effectiveness of incretin-based therapies. These include glucagon-like peptide-1 receptor agonists (GLP-1RAs; e.g., semaglutide) and dual agonists (e.g., tirzepatide) targeting both glucose-dependent insulinotropic polypeptide and GLP-1 receptors, in patients with type 2 diabetes mellitus or for weight loss. We review data from clinical trials and recent Canadian and international economic models, identify emerging indications, and discuss limitations in current health-technology assessment frameworks. Implications for Canadian reimbursement are highlighted, with attention to price, patient selection, and outcome considerations.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

IncretinsCost-Benefit AnalysisDiabetes Mellitus, Type 2ObesityHypoglycemic AgentsHumansCanadaGlucagon-Like Peptide-1 Receptor AgonistsSemaglutideTirzepatideAnimalsCost-Effectiveness Analysis

Stichwörter der Autor:innen

incretin therapiesGLP-1RAscost-effectivenessobesitysemaglutidetirzepatide

Substanzen

IncretinsHypoglycemic AgentsGlucagon-Like Peptide-1 Receptor AgonistsSemaglutideTirzepatide

Autor:innen und Institutionen

  • Western University, London, ON, Canada.
  • Queen's University, Kingston, ON, Canada.
  • Women's College Hospital Research and Innovation Institute, Toronto, ON, Canada.
  • Leslie Dan Faculty of Pharmacy, University of Toronto, Toronto, ON, Canada.

ORCID-Profile: Mina Tadrous

Zitieren

APA

Awadalla, L., Iskander, S., Chu, C., & Tadrous, M. (2026). Cost-effectiveness of incretin therapies: a Canadian lens on diabetes, obesity, and emerging indications. Canadian Journal of Physiology and Pharmacology. https://doi.org/10.1139/cjpp-2025-0248

Vancouver

Awadalla L, Iskander S, Chu C, Tadrous M. Cost-effectiveness of incretin therapies: a Canadian lens on diabetes, obesity, and emerging indications. Canadian Journal of Physiology and Pharmacology. 2026. doi:10.1139/cjpp-2025-0248

BibTeX
@article{Awadalla2026,
  author = {Awadalla, Luke and Iskander, Siena and Chu, Cherry and Tadrous, Mina},
  title = {Cost-effectiveness of incretin therapies: a Canadian lens on diabetes, obesity, and emerging indications},
  journal = {Canadian Journal of Physiology and Pharmacology},
  year = {2026},
  doi = {10.1139/cjpp-2025-0248}
}
Kostenlos starten →